BiondVax to Present Phase IIa Results at 2011 BIO International Convention

BiondVax to Present Phase IIa Results at 2011 BIO International Convention
Ness Ziona, Israel - 31 May 2011 - BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, is pleased to announce that the company's Chief Scientific Officer, Dr. Tamar Ben-Yedidia, will present the results of the Company's Phase IIa clinical trial at the 2011 BIO International Convention:
2011 BIO International Convention
27 - 30 June 2011, in Washington, D.C., USA
Title: Clinical progress towards a universal influenza vaccine
The Phase IIa clinical trial was a randomized, double-blind, placebo-controlled, multi-center, safety and immunogenicity study in 200 healthy volunteers, aged 18-49, being conducted at two clinical research centers in Israel. 
In February 2011, BiondVax announced positive interim safety results from the trial.  These results showed that no severe adverse events were found in any of the participants, further reinforcing the positive safety profile of the Multimeric-001 vaccine found in the Company's Phase I/II trials.
BiondVax is currently in the final stages of collecting and analyzing the data regarding the immunogenicity of the vaccine, and will announce the final results of the trial prior to the presentation at BIO at the end of June.
For further information, please contact:
Danny Aronovic
Public Relations Consultant
shapira marketingTel: +972 9 899 5813
Mob: +972 50 799 1121
[email protected]
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals ("the Company"), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza ("flu") Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against all human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.
BiondVax's innovative technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
BiondVax has successfully concluded two Phase I/II trials in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic.  The Company is now conducting a Phase IIa study, expected to be completed by mid-2011.
For further information on BiondVax, please visit